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Breast cancer consists of multiple diff  erent molecular subtypes and 
diff  erent biological processes, and consequently diff  erent molecular 
markers are associated with prognosis and chemotherapy sensitivity in 
the distinct disease subsets [1]. A large number of biological processes 
including cell cycle regulation, DNA replication, mitotic spindle 
checkpoint, and p53 function are strongly prognostic in ER+ cancers 
but not among ER– cancers [2,3]. Interestingly, the number of biological 
pathways, and therefore genes, that are associated with prognosis or 
treatment sensitivity are substantially larger and more consistent in ER+
cancers than among ER– tumors [1,4]. This implies that it is easier to 
discover prognostic and predictive markers for ER+ than for ER– cancers. 
In ER– cancers, the single most consistent, but still modestly accurate, 
good prognostic predictor is the presence of immune cell infi  ltration 
[5]. Immune cell signatures are also associated with more favorable 
prognosis in highly proliferative ER+ cancers but not in ER+ cancers with 
low proliferation [6].
It is also increasingly clear that the same molecular marker can be 
associated with several diff   erent outcome endpoints in various 
and often opposing manners. For example, high Ki67 expression 
is predictive of worse prognosis in the absence of any systemic 
therapy in ER+ cancers, but at the same time it is also predictive of 
higher sensitivity to chemotherapy. Similar opposing bidirectional 
associations with treatment response and prognosis exist for many 
other markers including histologic grade, Tau protein expression and 
almost all prognostic gene signatures [7].
It is important to be aware of these complex multi-directional 
interactions between molecular markers and various clinical endpoints 
that may also vary from breast cancer subtype to subtype. Ignoring 
these potential marker–disease subset–outcome interactions can lead 
to contradictory and confusing results across studies (due to diff  erences 
in patient composition and heterogeneity of therapy between studies) 
and may also lead to the discovery of biomarkers that are clinically less 
useful (because of unrecognized subtype-restricted performance) [8,9].
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Triple-negative breast cancers (TNBCs) are among the most clinically 
challenging because of their poor prognosis and paucity of treatment 
options. In part through our genomic profi  ling studies, breast cancer 
is now appreciated as being composed of multiple diseases. One of 
these diseases, the basal-like breast cancer (BLBC) subtype, is now 
known to represent a unique disease entity with a distinct etiology 
and biology. Over the years, BLBC has become more commonly 
known as TNBC because the majority of these tumors lack expression 
of ER, PR and HER2; however, not all TNBC are BLBC, and not all BLBC 
are TNBC. Recently, we discovered that a signifi  cant subset of TNBC 
is comprised of a new subtype, the claudin-low, which is important 
because it is biologically distinct from BLBC and has a number of 
features reminiscent of mammary stem cells [1]. In addition, luminal A, 
luminal B, and HER2-enriched tumors are also identifi  ed within TNBCs 
in various small proportions, which highlights the complexity of the 
clinically based classifi  cation.
We have explored the treatment sensitivity of the various intrinsic 
subtypes to neoadjuvant anthracycline/taxane-based chemotherapy 
using a large publicly available dataset [2]. Across all patients, and 
within TNBC, basal-like tumors were found associated with a higher 
likelihood of achieving a complete pathological response (pCR) than 
the rest of the subtypes, including the claudin-low. In multivariate 
logistic regression models for pCR prediction, we observed that the 
intrinsic molecular subtypes virtually always make the fi  nal model, 
even if clinical variables and other genomic predictors are included. 
In addition, our analyses show that those tumors that achieve a pCR 
showed a better survival outcome than those that did not, regardless 
of their molecular subtype; this eff   ect is much larger within the 
basal-like subtype, which is concordant with previous fi  ndings. This 
intriguing association between residual disease after therapy and poor 
outcome in basal-like and claudin-low tumors points to intratumor cell 
heterogeneity as a possible explanation, where resistant and aggressive 
cell clones might already exist in the pretreated tumor. Our preliminary  © 2010 BioMed Central Ltd
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and global gene expression on numerous preclinical models of basal-
like breast cancers including cell lines and primary tumor xenografts 
suggest the existence of at least two cell populations in many BLBC 
models. These diff  erent cell populations are currently being tested for 
tumor-initiating cell activities, and additional studies focusing on these 
populations changing with treatment are also being performed.
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Poly(ADP-ribose) polymerase-1 (PARP-1) is a nuclear DNA-binding 
enzyme activated by DNA strand breaks and has a key role in the 
signalling of DNA single-strand breaks as part of the repair process. 
In anti-cancer therapy, many agents cause DNA damage as their 
mechanism of cytotoxicity, and repair of damage is a cause of tumour 
resistance. Additionally in tumours where double-strand break repair 
is defective (for example in BRCA-related cancers) PARP inhibitors 
have potential single-agent activity. Thus, PARP-1 was identifi  ed 
as a potential therapeutic target for cancer treatment and PARP 
inhibitors have entered the clinic both in combination with cytotoxic 
chemotherapy, as single agents in DNA repair defi  cient tumours, and 
more recently in combination with radiotherapy.
The fi  rst PARP inhibitor to be given to cancer patients in 2003 was 
AG014699 (rucaparib), a tricyclic indole, which is a potent intravenous 
inhibitor of PARP. This phase I study had a pharmacodynamic endpoint 
of PARP inhibition in PBMCs, demonstrating for the fi  rst time proof of 
mechanism of the class. Subsequently AZD2281 (olaparib) entered 
clinical trials as a single agent (2005), and demonstrated the proof of 
concept of synthetic lethality in BRCA defective tumours in two small 
phase II studies. Over the last 5 years seven further inhibitors have entered 
cancer clinical trials either as a single agent (MK4827) or in combination 
with various cytotoxic regiments (ABT888, veliparib; BSI-201, iniparib; 
CEP-9722; INO-1001; E7016, BMN 673) in late preclinical development.
Initial exciting data suggesting that iniparib improved outcome 
in patients with triple-negative breast cancer in combination with 
chemotherapy have not been confi  rmed in phase III studies, although 
there are clearly patients who benefi  t from this agent. In terms of 
mechanism of action, iniparib diff  ers from all the other compounds 
in the class that are competitive inhibitors at the NAD+ binding site of 
PARP. Iniparib is postulated to have a diff  erent mechanism of action 
and may not be a bona fi  de PARP inhibitor.
It has been a period of rapid clinical development of a new class of 
agents with exciting evidence of improved response rates in some 
tumour areas. This class of agents also presents some interesting 
challenges in clinical trial design, and mechanistic understanding. This 
presentation will overview the current clinical status of PARP inhibitors 
and will discuss these challenges and potential biomarker strategies.
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Evading immune destruction should be considered an emerging 
hallmark of cancer [1]. Highly immunogenic cancer cells can be 
eliminated in immunocompetent hosts as a result of the immunoediting 
process. Weakly immunogenic variants can grow and generate solid 
tumours. Regulatory T cells (Tregs) were found to be involved in the 
maintenance of the immune tolerance both preventing autoimmune 
disease and curtailing antitumour immune response. Modulation of 
immune response in cancer patients is the result of a balanced activity 
of Tregs and T-eff  ector cells [2]. In cancer patients, an increased number 
of Tregs was found in blood and tumour tissue: it was demonstrated 
that Tregs suppress T-cell response and natural killer cell proliferation 
and function, thus interfering both with acquired and innate immunity. 
Upregulation of Tregs in the tumour bed can be associated with worse 
prognosis [3]. Drugs blocking function of Tregs increase activity of T 
eff  ectors and, as a side eff  ect, induce an autoimmune disease. Issues of 
biology and prognosis of breast cancer in the presence of a deregulation 
of the immune system need to be studied. The identifi  cation  of 
immunological and genetic features aff  ecting immune response in 
patients with minimal tumour burden is the optimal background for 
development of clinical studies in the adjuvant setting. Research on 
tumour-associated antigens (TAAs) has identifi  ed a large collection of 
peptide epitopes that have been and are being used for vaccination 
of cancer patients [4]. Several potential advantages of using peptide-
based vaccines include: easy and relatively inexpensive production 
of synthetic peptides; the easy administration of peptides in a clinical 
setting; the possibility of treating only those patients whose tumours 
overexpress the target antigens; and the availability of in vitro or ex vivo 
assays that can assess patients’ immune response to vaccine epitopes. 
The aim of future studies will be to assess the immunoreactivity of 
several antigens in a large series of breast cancer samples classifi  ed 
according to molecular subtypes. Identifi  cation of potential targets in 
subpopulations of patients with breast cancer may allow identifi  cation 
of patients who are potential candidates for adjuvant therapeutic 
vaccines. It is our current thinking that patients with minimal residual 
disease after preoperative chemotherapy are the ideal setting to test 
the effi   cacy of a vaccination strategy. To date, vaccines for breast cancer 
have been mainly used in end-stage disease. TAA antigens off  er a novel 
opportunity for fostering vaccine development and therapy.
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Epithelial–mesenchymal transition (EMT) is a major process controlling 
multiple events during development. EMT has been conserved 
throughout evolution to control morphogenetic events, such as the 
formation of the three primary germ layers during gastrulation. Most 
interestingly, signal transduction pathways have been remarkably 
conserved in many diff  erent species. EMT pathways are also tightly 
connected to determination and diff  erentiation  programmes, 
and are reactivated in adult tissues following injury or exposure 
to toxic agents. EMT is likely to operate during the early stages of 
carcinoma invasion that lead to blood or lymph vessel intravasation. 
Mesenchymal-like carcinoma cells undergo a mesenchymal-to-
epithelial transition in distant sites from the primary tumour and 
eventually become micrometastatic.   We have characterised bone 
marrow micrometastases from breast cancer patients and found that 
the detection of micrometastatic carcinoma cells was associated with 
poorer distant metastasis-free survival, local relapse-free survival, and 
overall survival. Despite high rates of adjuvant systemic treatment and 
breast irradiation in this series, disseminated carcinoma cells remain a 
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distant disseminated cancer cells in bone marrow-positive patients. In 
addition, we detected micrometastatic carcinoma cells in patients with 
T1 tumours, suggesting that dissemination occurs much earlier during 
tumour progression than is generally accepted. Thus, bone marrow 
micrometastases should become a very useful prognostic indicator 
for relapse, and an excellent surrogate marker for patient’s response to 
treatment. The mesenchymal-like state of carcinoma confers stemness, 
protection from cell death, escape from immune response and, most 
importantly, resistance to conventional and targeted therapies. 
Current strategies based on the EMT concept are aimed at designing 
new therapeutic approaches that interfere with the plasticity of 
carcinoma cells. Our laboratory has devised a high-content, high-
throughput screen for EMT. Several combinations of drugs have been 
shown to selectively inhibit EMT. This strategy may be used to interfere 
with tumour progression, particularly in breast carcinomas that have 
acquired resistance to conventional therapies.
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DNA methylation and histone modifi   cations have important roles 
in normal mammary diff  erentiation and the development of breast 
cancer. Epigenetically mediated silencing of tumor suppressor coding 
genes and microRNAs is a hallmark of human breast tumors. CpG 
island hypermethylation is starting to be used as a biomarker of the 
disease, such as BRCA1 hypermethylation as a predictor of response to 
PARP inhibitors. Most importantly, both DNA methylation and histone 
modifi  cations are new targets for upcoming drugs.
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Breast cancer risk is increased in women who have attributes of the 
insulin resistance syndrome, such as obesity (postmenopausal), central 
obesity (premenopausal and postmenopausal), high endogenous 
insulin levels, clinical diabetes and physical inactivity. There is a large 
body of evidence that obesity is associated with a 25 to 50% relative 
increase in risk of breast cancer recurrence or death, with adverse 
eff  ects that appear to be independent of hormone receptor status. 
Obesity, particularly when it is central, is strongly associated with 
insulin resistance in healthy individuals and breast cancer patients. 
Several studies have shown that higher insulin and/or C-peptide levels 
(a marker of insulin secretion), both of which are linked to insulin 
resistance, are associated with an increased risk of recurrence and 
death in women with early stage breast cancer, even in the absence 
of diabetes. Risk is increased twofold to threefold in those with 
insulin levels in the highest (versus lowest) quartile. Data from our 
group suggest that these prognostic associations of insulin are most 
marked in the fi  rst 5 years post diagnosis. A role of insulin in breast 
cancer outcomes is biologically plausible given overexpression of 
insulin receptors (IR), most frequently the fetal form of the receptor 
(IR-A), by the majority of human breast cancers. IR-A often hybridizes 
with insulin-like growth factor 1 receptors to stimulate mitogenic 
signaling pathways; hybrid receptor activation has been associated 
with poor clinical outcomes. The current observational and preclinical 
evidence linking insulin to breast cancer is suffi   ciently compelling that 
neoadjuvant and adjuvant intervention studies have been initiated to 
evaluate clinical anti-cancer eff  ects of metformin, an agent that lowers 
insulin levels and has other potential non-insulin-mediated anti-cancer 
eff   ects (mainly through activation of adenosine monophosphate-
activated protein kinase). Early results from window of opportunity 
neoadjuvant studies suggest short-term, single-agent metformin (2 
to 3 weeks) lowers insulin levels, reduces proliferation and increases 
apoptosis. NCIC MA32, an ongoing randomized, multicenter, placebo-
controlled, adjuvant trial involving 3,582 women with early stage 
breast cancer, will provide more defi   nitive evidence regarding 
potential anti-cancer eff  ects. Additional studies of metformin in the 
metastatic setting are underway and/or planned. Because other factors 
(such as infl  ammation, adipocytokines (leptin, adiponectin), higher 
estrogen levels) may also mediate prognostic eff  ects of obesity and/or 
insulin resistance in breast cancer, additional research targeting these 
mediators as well as obesity per se is also needed.
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The phosphatidylinositol-3 kinase (PI3K) pathway is overall the 
most frequently mutated pathway in cancer, with mutation and/or 
amplifi  cation of the genes encoding the PI3K catalytic subunits p110α 
(PIK3CA) and p110β (PIK3CB), the PI3K regulatory subunit p85α (PIK3R1), 
receptor tyrosine kinases (RTKs) such as HER2 (ERBB2) and FGFR1, the 
PI3K activator K-Ras, the PI3K eff  ectors AKT1, AKT2, and PDK1, and loss 
of the lipid phosphatases PTEN and INPP4B. PI3K is activated by growth 
factor RTKs and G-protein-coupled receptors (GPCRs). PI3K activates 
Akt, which, in turn, phosphorylates and inactivates Tuberin (TSC2), a 
GTPase-activating protein of the Ras homologue Rheb. Inactivation of 
Tuberin allows GTP-bound Rheb to accumulate and activate the mTOR/
Raptor (TORC1) complex, which regulates protein synthesis and cell 
growth. mTOR also couples with Rictor to form the TORC2 complex, 
which phosphorylates and activates AKT.
Class IA PI3K isoforms are heterodimeric lipid kinases that contain a 
p110 catalytic subunit and a p85 regulatory subunit. The three genes 
PIK3CA, PIK3CB, and PIK3CD encode the homologous p110α, p110β, and 
p110δ isozymes, respectively. Expression of p110δ is largely restricted 
to immune and hematopoietic cells, whereas p110α and p110β are 
ubiquitously expressed. p110α is essential for signaling and growth of 
tumors driven by PIK3CA mutations, RTKs, and/or mutant Ras, whereas 
p110β lies downstream of GPCRs and has been shown to mediate 
tumorigenesis in PTEN-defi  cient cells. PIK3CA mutations are the most 
commonly known genetic alterations of this pathway in cancer, where 
≥80% occur within the helical (E542K and E545K) and kinase (H1047R) 
domains of p110α. Such mutations confer increased catalytic activity 
through diff   erent mechanisms, but both induce characteristics of 
cellular transformation including growth factor-independent and 
anchorage-independent growth, and resistance to anoikis.
Several drugs targeting multiple levels of the PI3K network (that is, 
PI3K, AKT, mTOR) have been developed. A number of ATP-mimetics 
that bind competitively and reversibly to the ATP-binding pocket of 
p110 are in early clinical development. These include the pan-PI3K 
inhibitors BKM120, XL-147, PX-866, PKI-587, and GDC-0941, the p110α-
specifi  c inhibitors BYL719, GDC-0032, and INK-1117, the p110δ-specifi  c 
inhibitor CAL-101, and the dual PI3K/mTOR inhibitors BEZ235, BGT226, 
PF-4691502, GDC-0980, and XL-765. The pan-PI3K and p110α-specifi  c 
inhibitors are equally potent against oncogenic p110α mutants. The 
rationale for the development of isozyme-specifi  c antagonists is to 
allow higher doses of anti-p110α and anti-p110β drugs to be delivered 
without incurring side eff  ects caused by pan-PI3K inhibitors. Interim 
results from a phase I trial with the p110δ-specifi  c inhibitor CAL-101 
in patients with hematologic malignancies showed that treatment 
reduced P-AKT levels >90% in peripheral blood lymphocytes and 
induced objective clinical responses. Recently completed phase I trials 
with BKM120, BEZ235, and XL-147 showed that treatment partially 
inhibited PI3K as measured by levels of P-S6 and P-AKT in patients’ skin 
or tumors, and 2-deoxy-2-[18F]fl  uoro-D-glucose uptake measured by 
PET. Main toxicities were rash, hyperglycemia, diarrhea, fatigue and, 
mood alterations. Few clinical responses were observed in patients 
with and without detectable PI3K pathway mutations, although 
screening for genetic lesions in this pathway was not comprehensive.
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of AKT are also being developed. AZD5363, GDC-0068, GSK2141795, 
and GSK690693 are ATP-competitive compounds that have shown 
antitumor activity in preclinical models and recently entered phase I 
trials. Allosteric inhibitors such as MK-2206 bind to the AKT PH domain 
and/or hinge region to promote an inactive conformation of the AKT 
protein that is unable to bind to the plasma membrane. MK-2206 
inhibits AKT signaling in vivo, and suppresses growth of breast cancer 
xenografts harboring PIK3CA mutations or ERBB2 amplifi  cation. Phase 
I data showed that treatment with MK-2206 decreases levels of P-AKT, 
P-PRAS40, and P-GSK3β in tumor cells, peripheral blood mononuclear 
cells, and hair follicles.
The mTOR kinase is a component of PI3K-driven oncogenesis that 
functions within two signaling complexes: TORC1 and TORC2 
(described above). The macrolide rapamycin and its analogs form 
complexes with FK506-binding protein (FKBP12). This complex then 
binds to mTOR and inhibits the kinase activity of TORC1 but not TORC2. 
Formulation problems of rapamycin prompted the development of 
analogs such as CCI-779 (temsirolimus), RAD001 (everolimus), AP-
23573 (deferolimus), and MK-8669 (ridaferolimus). These rapalogs 
have shown cytostatic activity in preclinical models and clinical trials, 
particularly in patients with renal cell cancer, and in patients with 
mutations in the TSC complex (upstream of TORC1) who harbor renal 
angiolipomas. Compounds that target the ATP-binding cleft of mTOR 
(that is, OSI-027, AZD8055, INK-128), and are thus active against both 
TORC1 and TORC2, are also in phase I trials.
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The discovery and cloning of BRCA1 and BRCA2 was accompanied by 
optimism that these achievements would usher in a new era of insight 
into sporadic breast cancer. This optimism was fueled by precedents 
in other cancer types, where tumor suppressor genes identifi  ed in rare 
hereditary cancer syndromes proved to be involved in some, if not all, 
of the cases of sporadic cancer of the same type. In sporadic breast 
cancer, sequencing eff  orts have failed to show signifi  cant numbers of 
cases of biallelic somatic mutation of either BRCA1 or BRCA2, dashing 
hopes of simply leveraging the understanding of BRCA1 and BRCA2 
into a better understanding of sporadic breast cancer.
Laboratory-based studies of BRCA1 and BRCA2 demonstrated that loss of 
function of either gene resulted in signifi  cantly increased susceptibility to 
certain forms of chemotherapy, including interstrand DNA cross-linking 
agents such as the platinum drugs and mitomycin C. More recently, loss 
of BRCA1 or BRCA2 function has also been shown to increase sensitivity 
to PARP inhibition, a fi  nding made possible as a result of increased 
understanding of the DNA repair implications of BRCA1 or BRCA2 loss. 
To a large extent, these laboratory-based observations have now been 
verifi  ed in clinical trials enrolling patients with hereditary breast cancer.
The implications of the discovery of BRCA1 and BRCA2 for treatment 
options in sporadic breast cancer are more complex. Based on a series 
of striking phenotypic similarities between the majority of sporadic 
triple-negative breast cancers and most cancers that arise in BRCA1 
heterozygotes, the hypothesis arose that perhaps many of these sporadic 
cancers might also share a similar lesion in DNA repair (BRCAness) with 
the BRCA1-related tumors. This notion has now been put to the test in 
ongoing clinical trials that treat sporadic triple-negative breast cancer 
patients with platinum agents, PARP inhibitors, or combinations. The 
current evidence for and against this hypothesis will be discussed.
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The newly discovered diff  erential expression in numerous tissues, key 
cellular processes and multiple diseases for several families of long and 
short noncodingRNAs (ncRNAs, RNAs that do not codify for proteins 
but for RNAs with regulatory functions), including the already famous 
class of microRNAs (miRNAs), strongly suggest that the scientifi  c and 
medical communities have signifi  cantly underestimated the spectrum 
of ncRNAs whose altered expression has signifi  cant consequences in 
diseases. miRNA and other short or long ncRNA alterations are involved 
in the initiation, progression and metastases of human breast cancer. 
The main molecular alterations are represented by variations in gene 
expression, usually mild and with consequences for a vast number of 
target protein coding genes. The causes of the widespread diff  erential 
expression of ncRNAs in malignant compared with normal cells can be 
explained by the location of these genes in cancer-associated genomic 
regions, by epigenetic mechanisms and by alterations in the processing 
machinery. miRNA and other short or long ncRNA expression profi  ling 
of human breast tumors has identifi   ed signatures associated with 
diagnosis, staging, progression, prognosis and response to treatment. 
In addition, profi  ling has been exploited to identify ncRNAs that may 
represent downstream targets of activated oncogenic pathways or that 
are targeting protein coding genes involved in cancer. Recent studies 
proved that miRNAs and noncoding ultraconserved genes are main 
candidates for the elusive class of cancer predisposing genes and that 
other types of ncRNAs participate in the genetic puzzle giving rise to 
the malignant phenotype. Last, but not least, the shown expression 
correlations of these new ncRNAs with cancer metastatic potential and 
overall survival rates suggest that at least some member of these novel 
classes of molecules could potentially fi  nd use as biomarkers or novel 
therapeutics in cancers and other diseases.
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Trastuzumab has altered the natural history of HER2+ breast cancer. In 
the metastatic setting, it has improved progression-free and overall 
survival. In patients with operable breast cancer, adjuvant trastuzumab, 
when added to chemotherapy, has improved disease-free and overall 
survival. Unfortunately, virtually all patients with metastatic breast 
cancer develop disease that is at least partially resistant to trastuzumab. 
In these patients, there is still value in continuing trastuzumab in 
combination with other treatments, but trastuzumab alone is unable 
to fully suppress tumor growth. Multiple mechanisms of resistance 
to trastuzumab have been suggested including activation of other 
growth factor receptors, preferential fi  nding of HER2 to HER3, loss 
of the extracellular domain of HER2, and activation of the PI3 kinase 
pathway as a result of PTEN loss or a PIK3CA mutation. It is unknown 
to what extent these mechanisms are relevant in individual patients, 
but it is probable that many diff  erent mechanisms of resistance are 
clinically important. Over the past decade, a number of treatments 
have been developed for patients with trastuzumab-resistant disease. 
At present, only lapatinib, a small-molecule inhibitor of HER1 and HER2, 
is commercially available. It is active when administered with either 
chemotherapy or trastuzumab. A variety of other therapies are under 
investigation in phase III clinical trials. Pertuzumab, a monoclonal 
antibody that inhibits HER2–HER3 heterodimers, appears to be 
eff  ective when combined with trastuzumab ± chemotherapy. T-DM1, 
an antibody–drug conjugate, has also displayed remarkable activity in 
the setting of refractory disease and has limited toxicity. It is presently 
under investigation in multiple randomized trials. Neratinib is an oral 
irreversible tyrosine kinase inhibitor that targets HER1, HER2, and HER4. 
As a single agent, it appears to be more active than lapatinib, but is 
associated with more signifi  cant toxicity. It, too, is under evaluation 
in phase III trials in the adjuvant and metastatic settings. A variety of 
other agents are under active study including the mTOR inhibitors, the 
PI3kinase inhibitors, angiogenesis inhibitors, and IGFR antagonists. It is 
likely that a number of new agents will be available for the treatment 
of HER2+ breast cancer in the next several years, and outcomes for this 
group of patients will continue to improve.
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Introduction  A double-blind, randomized, phase 2b screening trial 
(SOLTI-0701) of sorafenib, an oral multikinase inhibitor, in patients with 
HER2-negative advanced breast cancer (BC), showed a statistically 
signifi   cant improvement in progression-free survival (PFS) in the 
sorafenib + capecitabine arm versus the placebo + capecitabine arm: 
6.4 versus 4.1 months (hazard ratio = 0.58; one-sided P = 0.0006). Grade 
3/4 toxicities were comparable except G3 hand–foot skin reaction/
syndrome (HFSR/HFS) (44% vs. 14%). These results support a phase 3 
trial of sorafenib + capecitabine in advanced BC.
Methods  RESILIENCE is an ongoing multinational, double-blind, 
placebo-controlled, phase 3 trial designed to assess sorafenib + 
capecitabine as fi  rst-line or second-line therapy in advanced HER2-
negative BC (ClinicalTrials.gov, NCT01234337). Eligibility criteria include: 
≥18 years of age; ≤1 prior chemotherapy regimen for advanced BC; 
resistant to/failed taxane and anthracycline or no indication for further 
anthracycline; no prior VEGF treatment. Patients are randomized to 
capecitabine (1,000 mg/m2 p.o. twice daily, days 1 to 14 of 21) with 
sorafenib (p.o. twice daily, days 1 to 21, total dose 600 mg/day) or 
placebo. Sorafenib 600 mg/day corresponds to the average daily dose 
during SOLTI-0701 that was eff  ective and manageable. Doses can be 
escalated to 2,500 mg/m2 and 800 mg/day or reduced to manage 
toxicity. Dose re-escalation after reduction is only allowed for sorafenib/
placebo. Guidelines detail prophylactic and symptomatic therapy for 
HFSR/HFS. Radiographic assessment is every 6 weeks for 36 weeks, 
then every 9 weeks. The primary endpoint is PFS. Secondary endpoints 
include overall survival, time to progression, overall response rate, and 
duration of response. Enrollment began in November 2010 and targets 
~519 patients.
Conclusion RESILIENCE will provide defi  nitive PFS data for sorafenib + 
capecitabine as fi   rst-line or second-line therapy in HER2-negative 
advanced BC and will better characterize the benefi  t-to-risk profi  le of 
this regimen.
O13
Molecular heterogeneity of luminal breast cancer
S Loi
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Luminal (or clinically defi  ned as estrogen receptor (ER)-positive and 
Her2-negative) breast cancer has long been successfully treated with 
anti-estrogen therapy, the fi  rst targeted anti-cancer agent in breast 
cancer. Recently, molecular profi  ling approaches have allowed better 
identifi  cation of a poor prognostic subgroup; however, the biological 
mechanisms which contribute this phenotype are currently unclear.
With regards to defi   ning prognosis, it is clear that proliferation 
markers can clearly separate ER+/HER2– breast cancer into at least two 
prognostic groups. Immunohistochemistry using Ki67 at the protein 
level and prognostic gene signatures such as Mammaprint™, the 21-
gene Recurrence Score, the two-gene ratio and genomic grade all 
provide quantitative measurements of proliferation activity. However, 
a biologically relevant cut-off    does not exist. Molecular subtype 
defi  nitions using PAM50 or other gene expression-based classifi  ers 
do not provide a more concordant or reproducible luminal A or B 
defi  nition. Improved defi  nition and clinical management of luminal 
subtypes will come from an increased understanding of the molecular 
drivers of the phenotype.
Lately, PIK3CA and AKT1 mutations have been shown to be associated 
with the good prognosis luminal A phenotype whilst FGFR1 and 
ZNF703 amplifi  cations are responsible for about 25% of the luminal B 
phenotype. It is hoped that new genomic technologies such as next-
generation sequencing will off  er new insights into the biology of ER-
positive breast cancer. Recent next-generation sequencing studies 
have identifi  ed MAP3K1, ATR and MYST3 mutations in around 10% of 
ER+ breast cancer which may be associated with de novo endocrine 
therapy resistance. These, if shown to be driver oncogenes, may shed 
new light on the biology of endocrine nonresponsive breast cancer 
and inspire new treatment strategies. Finally, recent results from the 
BOLERO-2 trial suggest that metastatic ER+ disease may be eff  ectively 
treated with the addition of a mTORC1 inhibitor, which suggests for 
many patients with acquired endocrine therapy resistance, mTOR 
pathway activation plays a signifi  cant part in their tumor biology.
O14
Translational breast cancer research in luminal breast cancer
M Dowsett
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Luminal breast cancer constitutes almost all ER-positive tumours 
and as such constitutes around 75 to 80% of the disease. The luminal 
group is highly heterogeneous in terms of genetic aberrations such 
as mutations, amplifi   cations/deletions and translocations, and also 
phenotypic characteristics such as proliferation and the expression of 
oestrogen-dependent proteins such as PgR, TFF1 and GREB1. While 
assessment of some of these molecular characteristics at presentation 
can act as a guide to outcome, there remains substantial uncertainty 
in prognostic and predictive algorithms. Our approach has been to 
study the biological relationships by applying specifi  c suppressants 
of the synthesis of oestrogen – that is, aromatase inhibitors (AIs) – in 
the presurgical setting. The changes in proliferation (Ki67) that occur 
are related to treatment benefi  t and the residual Ki67 to residual risk of 
recurrence. In addition, the molecular changes can be characterized as 
intermediate endpoints of response.
The POETIC trial of 2 weeks’ AI or not in the window of time between 
diagnosis and surgery has now recruited over 2,000 patients (August 
2011). Biopsies taken before and after the AI are providing a uniquely 
powerful set of data to understand the mechanisms of response 
and resistance to oestrogen deprivation. Pilot work has indicated 
that although luminal B tumours have higher initial Ki67 levels, their 
antiproliferative response to an AI is proportionally similar to luminal A 
tumours, indicating a similar initial responsiveness but higher residual 
risk of recurrence.
O15
Interpretation and molecular validation of biomarker studies
JS Reis-Filho
Breakthrough Breast Cancer Research Centre, Institute of Cancer Research, 
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The development and implementation of biomarkers for the 
diagnosis and classifi   cation of breast cancers and stratifi  cation 
of breast cancer patients into clinically meaningful groups are 
essential for the realisation of individualised medicine. The accurate, 
robust and reproducible assignment of patients into subgroups of 
therapeutic relevance is of utmost importance. Breast cancer patient 
treatment decision-making currently relies on the analyses of a few 
immunohistochemical markers (for example, oestrogen receptor, 
progesterone receptor and HER2), fl  uorescence and/ or chromogenic 
in situ hybridisation, protein analysis of lysates, and quantitative 
real-time PCR. It has become clear, however, that these markers are 
not suffi   cient for the potential of individualised therapy to be fully 
realised. The advent of high-throughput technologies and their use 
in fundamental and translational research endeavours have led to 
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predictive factors, and therapeutic targets, which ultimately will need 
to be incorporated in clinical practice. Some of the major challenges in 
this process are to determine the accuracy of the research hypothesis, 
the exclusion of potential biases, and to defi  ne whether the reagents 
and methodologies are fi   t for purpose. This requires not only a 
thorough assessment of the accuracy, robustness and reproducibility 
of the markers and the methods for their analysis, but also an adequate 
contextualisation of the validity of a given biomarker. For instance, 
immunohistochemistry has become one of the major tools for the 
identifi   cation of expression of potential markers in cancer tissues; 
albeit at fi  rst glance trivial to perform, immunohistochemical analysis 
can be aff  ected by numerous parameters that can aff  ect its accuracy. 
Likewise, several gene expression profi   ling approaches for the 
identifi  cation of molecular subtypes of breast cancer have been shown 
not to assign the same patients into the same molecular subgroups 
consistently. Interpretation of in situ hybridisation is also fraught with 
diffi   culties. Discrepancies in the assessment of biomarkers have often 
been attributed to intra-tumour heterogeneity, without exclusion of 
sources of technical variation. The challenges for the interpretation of 
biomarker studies and validation of biomarkers in human tissues will 
be discussed.
Poster presentations
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Introduction The aim was to compare the clinical features and 
prognosis of tubular breast cancer with the rest of breast cancer grade I.
Methods We analysed all tubular breast cancer studied by the Breast 
Diseases Committee during the period 1990 to 2009, comparing the 
clinical features and prognosis of tubular breast cancer with the rest of 
breast cancer grade I. Disease-free survival was analysed with Kaplan–
Meier curves.
Results We studied 170 cases, 41 (24.1%) tubular breast cancer and 
129 (75.9%) the rest of breast cancer grade I. There were no diff  erences 
in the average age of patients with tubular breast cancer and breast 
cancer grade I (51.9 vs. 52.7), family history, parity, fertility treatment, 
nulliparous, menopausal status, tumour size, and hormonal receptors. 
HER2 receptors are more frequent in breast cancer grade I. Two cases of 
tubular breast cancer (4.8%) less than 15 mm had nodal involvement. 
In tubular carcinomas, disease-free survival at 5 years was 97% and was 
93% at 10 years. In the rest of grade I carcinomas, disease-free survival 
at 5 years was 95% and was 89% at 10 years.
Conclusion  Tubular breast cancer has an excellent prognosis and 
survival, but is a necessary axillary node study in all cases.
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Introduction We have shown that nestin expression is higher in breast 
carcinoma with a basal phenotype [1] and collagen triple helix repeat 
containing 1 (CTHRC1) and periostin may predict bone metastasis of 
breast cancer [2]. Our aim therefore was to examine the simultaneous 
role of nestin and CTHRC1 in breast cancer progression.
Methods  Archival formalin-fi  xed  paraffi   n-embedded  173  invasive 
breast cancer samples classifi  ed into WHO histotypes and luminal, triple-
negative and Her2 subtypes were immunohistochemically stained 
with CTHRC1, periostin, nestin and vimentin antibodies. Staining was 
evaluated with histoscore and neoangiogenesis was assessed as the 
number of nestin-positive new vessels. The degree of infl  ammation 
was evaluated on HE-stained slides. Data were statistically processed by 
nonparametric Mann–Whitney U test, Spearman correlation coeffi   cient 
and Pearson chi-square.
Results Both CTHRC1 stromal (P  = 0.013) and nestin epithelial 
expression (P = 0.001) were higher in the triple-negative subtype. We 
found strong association between nestin expression in cancer cells and 
CTHRC1 stromal expression in advanced stage patients (r = 0.614; P = 
0.007). Nestin expression was also associated with vimentin expression 
in breast cancer cells (r = 0.491; P <0.001). Both nestin and vimentin 
showed positive association with degree of infl  ammation, in particular 
in triple-negative patients (rφ = 0.422; r = 0.521; both P  <0.001). 
We observed higher nestin positivity in patients with lymph node 
metastases and high periostin stromal expression (P = 0.031).
Conclusion For the fi  rst time, we report an association between CTHRC1 
and nestin expression in patients with advanced breast cancer. Further 
investigation is needed to better clarify their role in infl  ammation and 
breast cancer progression.
Acknowledgements This work was supported by grants NS 9956-4 and 
MSM 6198959216.
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Introduction Circulating endothelial cells (CECs) are shed from 
vessels and enter the circulation refl   ecting endothelial damage. 
Increased numbers of CECs have been documented in cancer, and 
appear to correlate with progression of the tumor. Bevacizumab (B) in 
combination with CT improves progression-free survival (PFS) of fi  rst-
line treatments and may modify tumor cell intravasation and CEC/CTC 
levels.
Methods  Patients received B (10 mg/kg/2 weeks) combined with 
paclitaxel (P) 150 mg/m2 and gemcitabine (G) 2,000 mg/m2 days 1 
and 15 with a cycle each 28 days of therapy, until disease progression, 
unacceptable toxicity or withdrawal. CTC/CECs were measured in 7.5 ml 
blood at baseline and after the fi  rst cycle of treatment. Enumeration 
was performed by the CellSearch System (Veridex).
Results Median of follow-up was 16.28 months. Baseline CECs were 
available for 31 patients. Median value of baseline CECs was 130 
(minimum 4 to maximum 1,407) and 60.3 (minimum 0 to maximum 
349) in the second determination, P = 0.02. High levels of baseline CECs 
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10.8) compared with those with <200, PFS 16.9 months (95% CI = 8.78 to 
NA), P = 0.003. See Figure 1. No diff  erence was observed in OS. Fourteen 
patients (74%) that had stable disease/partial response decreased or 
maintained their CEC value. Baseline CTCs ≥5 was associated with 
a median PFS of 15.2 months (95% CI = 7.6 to 16.9). Twenty-two 
patients (92%) that had stable disease/partial response decreased or 
maintained their CTC value. The CTC level was not correlated with the 
CEC level, P = 0.74.
Conclusion Our study suggests signifi  cant correlations between high 
levels of baseline CECs and poor prognosis. Addiction of B to fi  rst-line 
CT was related to a high reduction of CEC and CTC count.
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Introduction Status of the surgical margins following wide local 
excision for breast cancer remains one of the strongest predictors 
of local recurrence. In our practice, a margin of 1 mm and more is 
considered adequate. In this study, we aim to determine whether 
clinicopathological factors other than surgical margins contribute to 
the risk of local recurrence.
Methods A retrospective review was performed of 548 consecutive 
patients who underwent wide local excision for invasive carcinoma or 
ductal carcinoma in situ (DCIS) from 1 January 2004 to 31 December 
2008. Surgery was not routinely off   ered to patients with margins 
of 1  mm or more. All patients with wide local excision received 
postoperative whole breast irradiation, inclusive of a boost to the 
tumour bed.
Results Local recurrence developed in 20% of those with involved 
margins, as compared with 8.7% of those with close margins, and 5.4% 
of those with margins of 1 mm and more. Although local recurrence 
was more likely with an involved or close surgical margin, this reached 
only borderline signifi  cance (P = 0.05). Oestrogen receptor (ER) status 
was found to be an independent predictor of local recurrence, with 
ER-negative tumours being three times more likely to recur (P < 0.01, 
OR = 0.30, 95% CI = 0.13 to 0.66). There was no correlation with a triple-
negative phenotype or other clinicopathological factors.
Conclusion  A margin of 1 mm or more appears to be adequate 
following wide local excision. However, ER status emerged as a 
stronger predictor for local recurrence and alone remained signifi  cant 
on multivariate analysis.
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Introduction Inside the luminal breast cancer (BC) group, the B subclass 
carries a worse prognosis and is less responsive to hormonal treatment. 
Identifi  cation of the luminal B group, by Sørlie and colleagues [1], has 
been less consistent than other subclasses; and gene signatures based 
in estrogen-related genes or proliferation are better to identify this BC 
subclass. Cheang and colleagues genetically evaluated 144 luminal ER-
positive HER2-negative tumors by IHC; they found a ki67 cutoff   value of 
13.25% to diff  erentiate B from A subclasses [2]. No diff  erentiation for PR 
status was done. The luminal B subgroup is usually defi  ned as ki67 >13 
if ER-positive, as well as HER2-positive or PR-negative. The target of this 
abstract is to evaluate behavior of diff  erent luminal B subsets.
Methods  We reviewed early BC cases evaluated at Hospital 12 de 
Octubre between 1995 and 2007 and selected 710 initially operated 
luminal B BC. We divided this group into four subsets as shown in 
Figure 1 (abstract P4).
Table 1 (abstract P6)
     HER2–
Variable HER2+ER+ ER+PgR– ER–PgR+ ER+PgR+ ki67 >13
Cases  189  126 10 385
Median age (P =  0.0021)  53.49  60.3 49.7 57.7
Ductal (P = 0.002)  173 (91.5%)  98 (77.8%)  10 (100%)  314 (81.5%)
HG III (P =  0.03)  41% 47% 40%  34.1%
Lobular 5.3%  17.5%  0  14%
Median  ER  85%  83% 0 90%
Median  PR  60% 0 45%  80%
Median  ki67  20%  17% 12.5% 20%
Recurrences total (%)  52 (27.5%)  32 (25.4%)  2 (20%)  81 (21%)
Locoregional  9 (17.3%)  3 (9.4%)  0  15 (18.5%)
Bone  6 (11.5%)  14 (43.8%)  0  25 (30.9%)
Visceral (P = 0.04)  34 (65.4%)  11 (34.4%)  0  36 (44.4%)
Median (95% CI) DFS (years)  8.1 (6.5 to 8.7)  6.4 (5.4 to 7.2)  9.2 (7.6 to 11.9)  5.6 (5.2 to 6.1)
Median (95% CI) OS (years)  8.7 (8.1 to 9.0)  7.0 (5.8 to 7.9)  10.5 (7.8 to 13.6)  6.1 (5.6 to 6.6)
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Additionally, we evaluated the prognostic behavior of lowering the 
ki67 cutoff   in the ER+PR+HER2– group (820 patients).
Results The median ki67 value for the ER+PR– group was 17%. A ki67 
cutoff   at 14% discerns two groups of diff  erent prognosis inside the 
luminal group (extracting HER2+ and PR–); and comparison of ki67 
cutoff   between 14 and 11% found overlapped CI (median: 6.31 (5.99 to 
6.62) vs. 6.49 (6.21 to 6.78)). Table 1 summarizes diff  erent characteristics 
and prognosis based on molecular features (statistical comparisons 
exclude the ER-–PR+ subgroup).
Conclusion  Subsets inside the luminal B subtype according to 
expression of HER2, ER, PgR and ki67 have diff  erent features and 
behaviors. In the ER+PR+HER2– subgroup, ki67 cutoff   should be re-
evaluated in order to avoid misclassifi  cation and subsequent under-
treatment of poorer prognosis tumors as luminal A hormono-sensitive 
phenotype.
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Introduction Invasive lobular carcinoma (ILC) is the second most 
common type of invasive breast cancer (BC), which comprises 
approximately 10% of BC and appears to have distinct biologic and 
epidemiologic characteristics.
Methods We analyzed data of 205 BC patients diagnosed with ILC 
who were diagnosed between January 1994 and December 2007. The 
objective was to determine the clinicopathological features, treatment 
and patterns of recurrence of ILC.
Results Median age was 58.5 (range: 29.6 to 87.3). One hundred and 
thirty-six patients (66.3%) were postmenopausal, 131 patients (63.9%) 
underwent mastectomy and 74 (36.1%) a conservative surgical 
procedure. Pathological features were: T1: 79 patients (38.5%); T2: 
84 patients (41%); T3: 19 patients (9.3%); T4: seven patients (3.4%); 
multifocal: 16 patients (7.8%). Nodal status N0: 131 patients (63.9%); 
N1: 41 patients (20%); N2: 16 patients (7.8%); N3: 17 patients (8.3%). 
Regarding phenotype, 90 patients (43.9%) were luminal A; 82 patients 
(40%) luminal B; 14 patients (6.8%) HER2+/RE+; two patients (1%) HER2+/
RE–; and seven patients (3.4%) were triple negative. Sixty-seven patients 
(32.7%) did not receive adjuvant chemotherapy (CT). Most frequent 
adjuvant QT received was anthracycline-based (61 patients, 29.8%) 
followed by CMF (42 patients, 20.5%) and anthracycline + taxane-based 
CT (35 patients, 17.1%). A total of 185 patients (90%) received adjuvant 
hormonal treatment, the most commonly used being tamoxifen (111 
patients, 60%) followed by up-front aromatase inhibitors (AI). With a 
median follow-up of 97.3 months, 47 patients (22.9%) had a relapse, 
with a median disease-free survival (DFS) of 184 months. Five-year and 
10-year DFS rates were 81.8% and 69.1%, respectively. T1, N0 tumors 
that received CT/HT/RT had a signifi   cantly lower recurrence rate 
(P <0.05). The most frequent metastatic site at recurrence was bone (18 
patients, 38%), followed by pleuropulmonar (seven patients, 15%), liver 
(fi  ve patients, 11%) and ganglionar (fi  ve patients, 11%). Median overall 
survival (OS) was not achieved; 5-year and 10-year OS rates were 94.4% 
and 81%, respectively. OS was signifi  cantly better (P <0.05) for T1, N0 
tumors.
Conclusion In this review of ILC patients, the most common phenotype 
was luminal A. Recurrence and death rates were low, bone being the 
most common site of relapse.
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Introduction Triple-negative breast cancers (TNBCS) are aggressive 
with poor prognosis. Patients cannot benefi  t from targeted treatment. 
Moreover, little is known of which TNBC patients will benefi  t from 
nontargeted adjuvant treatment. The objective was to search for 
predictors of adjuvant chemotherapy in TNBC.
Methods The study included 67 TNBC patients in clinical stages I to III, 
all but 22 had undergone adjuvant chemotherapy (CMF – 27 patients). 
FISH using p53, HER1, centromere 7 and 17 probes was performed on 
tumor tissue. Bcl2 was detected by immunohistochemistry.
Results HER1 amplifi  cation was found in 23.9%, p53 deletion was 
detected in 29.7% and bcl2 positivity was present in 32.8% tumors. A 
lower p53/chromosome 17 ratio correlated with higher grading (P = 
0.003) and showed a strong trend toward HER1/chromosome 7 ratio 
(P = 0.053). Patients with a chromosome 17 copy number ≥1.9 had 
better overall survival than patients with a copy number <1.9 (Kaplan–
Meier, P = 0.014). Bcl2-positive patients treated with adjuvant CMF had 
signifi  cantly better disease-free survival than bcl2-negative patients 
treated with adjuvant CMF (Kaplan–Meier, P <0.035).
Conclusion Initial data support the use of a classical CMF regimen 
in TNBC patients. However, the biomarker of CMF responsiveness 
is needed for clinical practice. We confi  rmed the bcl2 positivity as a 
predictor of CMF sensitivity in TNBC. Thus, validation of this marker 
in a larger study is needed. Higher chromosome 17 copy number was 
associated with better outcome, suggesting the importance of its 
assessment.
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Introduction In breast cancer (BC), several cytogenetic markers are 
routinely investigated (Her2, progesterone and estrogen receptors) 
that distribute patients into diff  erent diagnostic groups, determine 
prognosis and predict eff   ectiveness of therapy. Additional genetic 
markers can improve prediction or prognosis in BC patients. C-MYC 
and CCND1 gene aberrations frequently found in BC were chosen for 
this study.
Methods  The status of C-MYC, CCND1 genes, chromosomes 8 and 
11 were determined on 74 patients from a group of 103 BC patients 
treated with herceptin in a palliative regime, using FISH assay on 
formalin-fi  xed paraffi   n-embedded tissue samples. One hundred nuclei 
per sample were analyzed in each sample. Clinical data were correlated 
with our cytogenetic results.
Results Amplifi  cations of CCND1 and C-MYC were occurring together 
in most cases (P <0.0001), especially in Her-2/neu-negative cases (P = 
0.01, resp. 0.03). Progesterone receptor positivity was associated with 
CCND1, resp. C-MYC increased copy number (P = 0.039, resp. 0.038). 
Amplifi  cation (ratio gene/chromosome ≥2.2) of CCND1, resp. C-MYC 
was determined in 8.1% (6/74), resp. 12.2% (9/74) cases. Polysomy 
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S8(copy number ≥3.0) of chromosome 11, resp. 8 was determined in 6.8% 
(5/74), resp. 16.2% (12/74) cases.
Conclusion  Increased copy numbers of CCND1 and C-MYC were 
associated with progesterone receptor positivity and Her-2/neu 
negativity. Clinical relevance of our fi  ndings will be presented.
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Introduction microRNAs (miRNAs) constitute a new class of small 
noncoding RNAs that control post-transcriptionally the expression 
of gene products, either modulating directly protein translation or 
regulating the stability of messenger RNA. There is increasing evidence 
of the role that miRNAs play in regulating breast cancer gene expression. 
The main objective of this study is to evaluate the diagnostic utility of 
the expression of a panel of miRNAs in breast cancer and compare their 
expression with the expression of the proteins they regulate.
Methods miRNA expression was analyzed by RT-qPCR using TaqMan 
Arrays (Applied Biosystems). We compared the expression of 667 
miRNAs on 19 fresh frozen (FF) and formalin-fi  xed paraffi   n-embedded 
(FFPE) matched breast cancer samples. Regarding protein expression, 
we have developed and evaluated diff   erent protocols for protein 
extraction from FFPE samples. Next, we studied the applicability 
of these protein extracts to classical and new high-performance 
proteomics techniques.
Results After     proper normalization, 123 out of 671 miRNAs showed a 
good correlation of their expression data between FFPE and FF tissue, and 
suffi   cient analytical robustness (they are expressed in at least one-third of 
FFPE samples). In addition, we analyzed the expression of various markers 
with diagnostic value in breast cancer. As regards high-performance 
proteomics, the protocols developed generated over 6,000 MS/MS spectra, 
enabling the identifi  cation of hundreds of proteins in each sample.
Conclusion We have selected the most appropriate assays to study 
miRNA expression in breast cancer FFPE archived samples. The protocols 
developed allow proteome analysis of FFPE samples using the latest 
mass spectrometry equipment. The technologies implemented during 
the development of this project allow one to compare the expression 
data at both miRNA and protein levels to study breast cancer from an 
authentic system-biology perspective.
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Introduction Acquired resistance to endocrine therapies remains 
a major clinical obstacle in hormone-sensitive breast tumors. The 
complexity of the underlying biological mechanisms remains poorly 
understood and the purpose of this study was to identify low abundant 
proteins and central pathways associated with tamoxifen resistance.
Methods  The global protein expression of the parental tamoxifen-
sensitive MCF7S0.5 cell line and the tamoxifen-resistant TamR1 cell 
line were compared using SILAC labeling and quantitative mass 
spectrometry. Data were processed using MaxQuant, the global 
protein–protein interaction network was predicted using STRING 
and enriched pathways were identifi  ed with KEGG analysis. Selected 
proteins diff  erentially expressed were validated using western blotting 
and immunocytochemistry.
Results Proteomic analysis identifi  ed 5,370 proteins based on at least 
one unique peptide of which 4,448 proteins could be quantifi  ed 
based on at least two peptides. Forty-one proteins were found to be 
diff  erentially expressed more than threefold and eight proteins were 
validated by western blotting and immunocytochemistry as potential 
biomarkers associated with tamoxifen resistance. In total 539 proteins 
were diff  erentially expressed 1.5-fold or more and could be subgrouped 
into kinases, transcription factors, receptor activity proteins, cell 
adhesion proteins, cell cycle proteins and stress responder proteins. We 
identifi  ed several regulated proteins to be important in subnetworks 
that among others are involved in focal adhesion, DNA replication, 
apoptosis, and insulin and HER2 signaling pathway.
Conclusion Novel low abundant proteins not previously associated 
with tamoxifen resistance have been identifi  ed and validated using 
biochemical methods. At present the proteins are being validated on 
a panel of primary breast cancer biopsies from patients treated with 
tamoxifen monotherapy and with known clinical outcome. Our data 
also revealed several pathways associated to tamoxifen resistance. The 
importance of these pathways needs to be studied further.
P12
The miRNA-200 family and miRNA-9 exhibit diff  erential expression 
in primary versus corresponding metastatic tissue in breast cancer
KH Gravgaard1, MB Lyng1, A-V Laenkholm2, R Søkilde3, BS Nielsen3,4, 
T Litman3, HJ Ditzel1,5
1Department of Cancer and Infl  ammation Research, Institute of Molecular 
Medicine, University of Southern Denmark, Odense; 2Department of 
Pathology, Hospital South, Slagelse, Denmark; 3Department of Biomarker 
Discovery, Exiqon A/S, Vedbaek, Denmark; 4Current address: Bioneer, 
Hørsholm, Denmark; 5Department of Oncology, Odense University Hospital, 
Odense, Denmark
Breast Cancer Research 2011, 13(Suppl 2):P12 (doi: 10.1186/bcr3033)
Introduction Metastases are the major cause of cancer-related 
deaths, but the mechanisms of the metastatic process remain poorly 
understood. In recent years, the involvement of microRNAs (miRNAs) 
in cancer has become apparent, and the objective of this study was to 
identify miRNAs associated with breast cancer progression.
Methods  Global miRNA expression profi  ling was performed on 47 
tumor samples from 14 patients with paired samples from primary 
breast tumors and corresponding lymph node and distant metastases 
using LNA-enhanced miRNA microarrays. The identifi  ed  miRNA 
expression alterations were validated by real-time PCR, and tissue 
distribution of the miRNAs was visualized by in situ hybridization.
Results The patients in which the miRNA profi  le of the primary tumor 
and corresponding distant metastasis clustered in a unsupervised cluster 
analysis showed signifi  cantly shorter intervals between the diagnosis of 
the primary tumor and distant metastasis (median 1.6 years) compared 
with those that did not cluster (median 11.3 years) (P <0.003). Fifteen 
miRNAs were identifi  ed that were signifi  cantly diff  erentially expressed 
between primary tumors and corresponding distant metastases, 
including miR-9, miR-219-5p and four of the fi  ve members of the miR-200 
family involved in epithelial–mesenchymal transition. Tumor expression 
of miR-9 and miR-200b was confi  rmed using in situ hybridization, which 
also verifi  ed higher expression of these miRNAs in the distant metastases 
versus corresponding primary tumors.
Conclusion Our results demonstrate alterations in miRNA expression 
at diff  erent stages of disease progression in breast cancer, and suggest 
a direct involvement of the miR-200 family and miR-9 in the metastasis 
process.
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